Tom is a founder of Wintermute Biomedical and co-inventor of the patented carboxylate salt technology. He brings over 26 years of research experience to the team. Beyond his role at Wintermute Biomedical, Tom's background includes serving as staff scientist for Sinapis Pharma, Chief Scientific Officer for VirtualMind, and a founder of FYR Diagnostics. Throughout his career, he has led teams that successfully secured over $6 million in grants and $7.3 million in equity funding, driving significant scientific advancements.

Paul Field has over 30 years of business development experience across a range of therapeutic areas, and a deep network in the global biopharmaceutical industry. His current roles include Head of Business Development at Neurizon Therapeutics Ltd. (ASX:NUZ) and Non-Executive Director of 60 Degrees Pharmaceuticals(NASDAQ:SXTP). Paul is a Fellow of the Australian Institute of Company Directors (FAICD).

‍

Professor John Skerritt AM is an Enterprise Professor at the University of Melbourne and Adjunct Professor at the University of Sydney. Formerly Deputy Secretary of the Health Department and Head of the Therapeutic Goods Administration (2012–2023), he was a key public face during Australia’s COVID response. He chairs the Scientific Advisory Council of the Centre for Innovation in Regulatory Science and sits on the boards of the Centre for Regulatory Excellence (Singapore), Medicines Australia, and AusBiotech. An Order of Australia recipient with a PhD from Sydney University, he has over 300 publications and has commercialised numerous biotechnology products

Dr Margaret Hartley is a highly regarded executive leader and influential strategy and policy analyst with extensive experience in evidence-based policy development. Over her career, she has held senior positions, providing leadership in science, health, and innovation policy. Renowned for her strategic insight and forward-thinking approach, Margaret has guided complex policy reforms, organisational transformations, and national initiatives. She is recognised for her ability to connect scientific evidence with practical policy solutions, foster collaboration across sectors, and influence decision-making at the highest levels.

Bob Goodman is an investor and member of Wintermute Biomedical’s Board of Directors. A former mathematics instructor and practicing attorney focused on personal-injury and medical-related litigation, Bob brings a rare blend of analytical thinking and legal discipline to board deliberations. He contributes to governance, helps sharpen contracting and diligence processes, and supports management on stakeholder accountability. Bob’s background enables clear framing of complex issues, and pragmatic decision-making that aligns scientific ambition with responsible growth and long-term value creation.

‍

Alyce obtained her PhD from the La Trobe Institute for Molecular Science, La Trobe University. She specialises in cancer immunology, molecular and cell biology.

Alyce leads the ZosterEase™ shingles clinical trial program. Joining Wintermute in 2021, Alyce oversees the trials' research, protocol design, and clinical/regulatory strategy to advance evidence-based, patient-centred therapies to address current shingles treatment gaps.

Carolyn has a Pharmacology degree consolidated by 15 years in varied commercial roles within the pharmaceutical industry. She spent 10 years building a highly successful private mobility aids equipment business which was acquired in 2019 by a private equity investor. Carolyn brings a strength of operational and commercial expertise.

Dr Aaron Wong, MBBS (Hons) USYD, BPharm, FRACGP is a Sydney-based Primary Care Physician whose work spans several metropolitan practices. His clinical interests include preventative medicine, chronic disease management, infectious diseases, and herpes virus infections with a practical focus on diagnosis, treatment, and patient supporting primary care. He is a Principal Investigator and leads multiple clinical trials across these therapeutic areas. Dr. Wong is passionate about advancing innovative therapies and ensuring that trial design and execution remain closely aligned with the needs of patients and clinicians alike.

Dr. Lynn Scoles, MBBS, FRACGP, GAICD, has been a dedicated General Practitioner in Melbourne for more than 30 years, bringing deep experience in patient care, clinical education, and health management plans. She also serves as a reviewer for the Australian Family Physician journal, an examiner for the Royal Australian College of General Practitioners, and has previously been a lecturer in the Department of Community Medicine at Monash University. Additionally Lynn is a AICD graduate, a passionate Executive Coach, facilitating leadership programs. She brings deep clinical insight and rigour to Wintermute Biomedical’s clinical advisory board.

Dr Euan Mabon, MBChB, DRCOG, RCGP, FRACGP, is an experienced GP and medical educator who trained at the University of Glasgow and practised in the UK for over a decade before relocating to Melbourne. He provides holistic, evidence-based care and leads practice functions across finance, IT, marketing, research, training and education.

A dedicated mentor, he teaches University of Melbourne medical students, serves as lead supervisor for GP registrars, and is a clinical examiner for the RACGP. His focus is advancing modern, collaborative general practice through clinical excellence and continuous improvement.

Prof Levin, MD, FIDSA, FPIDS studies the immune response to herpes virus infections and methods of treating and preventing such infections, including antiviral therapy and active immunization. He does basic research on the nature of latency of herpes viruses in human neurons. A vaccine to prevent shingles in elderly individuals has been developed and licensed through his clinical research, and further investigations of this vaccine are in progress.

He is a Fellow of both the Infectious Diseases Society of America and the Pediatric Infectious Disease Society.

Prof Tony Cunningham, AO, FAHMS, MD, FRACP, FRCPA, FRSN is a highly experienced viral immunologist, infectious diseases clinician and scientist, well known internationally for his research on the immunology of HIV and herpesviruses, his work on vaccine development and trialling, especially for shingles and herpes, and as an antiviral expert.

Prof Cunningham has been a longstanding global consultant to GSK, Seqirus, and Merck on vaccines in the ageing and for shingles and herpes and recently to Moderna and Novavax for COVID vaccines.